Premium
Long‐term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies
Author(s) -
Reiner Peggy,
Galanaud Damien,
Leroux Gaëlle,
Vidailhet Marie,
Haroche Julien,
Huong Du Le Thi,
Francès Camille,
Papo Thomas,
de Gennes Christian,
Musset Lucile,
Wechsler Bertrand,
Amoura Zahir,
Piette JeanCharles,
CostedoatChalumeau Nathalie
Publication year - 2011
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.23863
Subject(s) - chorea , medicine , antithrombotic , antiphospholipid syndrome , thrombosis , surgery , pediatrics , disease
Objective: The aim of this work was to describe chorea during systemic lupus erythematosus or antiphospholipid antibodies and its long‐term outcome. Methods: We retrospectively analyzed clinical features, laboratory findings, imaging characteristics, and outcome in a series of 32 patients. Results: Most patients were women (28 of 32), and mean age at onset of chorea was 20.6 (9–62) years. Chorea was inaugural for 28 patients. Improvement was observed with various treatments. During follow‐up (12.2 ± 11.3 years), severe manifestations of systemic lupus erythematosus were rare. Antiphospholipid antibodies were repeatedly positive for 90% of the patients. Twelve patients developed arterial thrombosis. Prophylactic treatment with antithrombotic therapy might reduce the risk of further thrombosis (8% versus 57%; P = 0.01). Cardiac valvulopathy occurred in 22 patients during follow‐up. Chorea relapsed in 8 cases. Conclusions: Chorea had a good outcome in itself. This long‐term follow‐up shows, for the first time, that these patients have substantial risk for further arterial thrombosis. © 2011 Movement Disorder Society